| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Juan C Gea-Banacloche | |
| P433 | issue | 2 | |
| P304 | page(s) | 187-198 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Seminars in Hematology | Q15765535 |
| P1476 | title | Rituximab-associated infections | |
| P478 | volume | 47 |
| Q38992084 | A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma |
| Q85624158 | A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy |
| Q40302214 | Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. |
| Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
| Q42678843 | Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. |
| Q36109213 | Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes |
| Q38163603 | B cells participate in tolerance and autoimmunity through cytokine production |
| Q89120053 | Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies |
| Q28080304 | Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy |
| Q53625850 | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. |
| Q39017396 | Complications of nephrotic syndrome |
| Q47813195 | Effect of rituximab on primary central nervous system lymphoma: a meta-analysis |
| Q92223049 | Efficacy and Safety of Ultra-Low-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in High-Risk Kidney Transplantation Patients |
| Q39487696 | Emerging trends in the formation and function of tuberculosis granulomas |
| Q37912229 | Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation |
| Q47560065 | Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy |
| Q40058074 | Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report |
| Q54366957 | Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. |
| Q42548719 | Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012. |
| Q55154606 | Following Acute Encephalitis, Semliki Forest Virus is Undetectable in the Brain by Infectivity Assays but Functional Virus RNA Capable of Generating Infectious Virus Persists for Life. |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q35582198 | HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition |
| Q34718363 | Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. |
| Q40144152 | Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. |
| Q51668984 | High affinity anti-BSEP antibodies after liver transplantation for PFIC-2 - Successful treatment with immunoadsorption and B-cell depletion. |
| Q34663197 | Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis |
| Q42764680 | Immunosuppression in Patients with Chronic Hepatitis B. |
| Q35237511 | Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? |
| Q38036246 | Incompatible kidney transplantation: a brief overview of the past, present and future. |
| Q40331569 | Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy |
| Q37906737 | Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. |
| Q40996415 | Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma |
| Q44187530 | Limbic encephalitis and related cortical syndromes |
| Q42229459 | Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? |
| Q33399639 | Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements |
| Q37690737 | Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections |
| Q42178052 | Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. |
| Q26853490 | Management of patients with hepatitis B who require immunosuppressive therapy |
| Q38218566 | Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. |
| Q26826880 | Monoclonal antibody therapy and renal transplantation: focus on adverse effects |
| Q35151851 | Multiple sclerosis: pathogenesis and treatment |
| Q53086368 | Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. |
| Q38057370 | New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment. |
| Q36253983 | Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib |
| Q92833865 | Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice |
| Q37128026 | Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review |
| Q40424187 | Pneumocystis jirovecii Pneumonia in a Treatment-Naive Patient With Chronic Lymphocytic Leukemia |
| Q87056543 | Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy |
| Q87423509 | Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy |
| Q37919869 | Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand? |
| Q35613669 | Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis |
| Q37019872 | Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis |
| Q89835028 | Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature |
| Q37988317 | Rheumatoid arthritis and the era of biologic therapy |
| Q30500238 | Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis |
| Q40275275 | Rituximab and hepatitis B reactivation in HBsAg-negative/ anti-HBc-positive kidney transplant recipients. |
| Q38235185 | Rituximab and lupus--a promising pair? |
| Q51012123 | Rituximab and memory antibody levels after desensitization |
| Q49866575 | Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. |
| Q36109197 | Rituximab in idiopathic membranous nephropathy |
| Q41791124 | Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation |
| Q51004424 | Rituximab therapy for refractory idiopathic scleritis. |
| Q41439263 | Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study |
| Q37944433 | Safety of biologic therapy in rheumatoid arthritis |
| Q34542922 | Safety of monoclonal antibodies for the treatment of multiple sclerosis. |
| Q102206480 | Selective depletion of antigen-specific antibodies for the treatment of demyelinating disease |
| Q43052115 | Severe CMV complication following maintenance therapy with rituximab |
| Q45355413 | Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy |
| Q56529806 | Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide |
| Q37732218 | Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide |
| Q26783195 | Targeted Therapies in Adult B-Cell Malignancies |
| Q27002843 | Targeting the Fc receptor in autoimmune disease |
| Q39531026 | Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease |
| Q34374056 | The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. |
| Q37922370 | The cryoglobulinaemias |
| Q40670409 | The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. |
| Q35104199 | The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system |
| Q28478591 | Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies |
| Q59111383 | Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro |
| Q26773178 | Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review |
| Q39410091 | Treatment of membranous nephropathy: time for a paradigm shift |
| Q38871098 | Unintended Immunological Consequences of Biologic Therapy. |
| Q42269861 | Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma |
| Q38635750 | West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of Literature. |
| Q82387535 | [Vaccinations in rheumatology] |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.